Takeda (TYO:4502) and TiGenix (EBR:TIG) today touted long-term data from its phase III Admire-CD trial evaluating its suspension of allogenic expanded adipose-derived stem cells, Cx601, in patients with Chron’s disease. The study showed that Cx601 maintained long-term remission of treatment refractory complex perianal fistulas over 52 weeks.
The randomized, phase III trial compared Cx601 to a placebo control, which researchers gave in combination with standard of care. A significantly greater proportion of patients in the stem cell therapy group met clinical and radiological combined remission compared to their counterparts in the control arm after 52 weeks. The rates and types of treatment related adverse events were similar in both groups, the companies reported.